Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) EBT (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of EBT data on record, last reported at -$164.0 million in Q4 2025.

  • For Q4 2025, EBT changed N/A year-over-year to -$164.0 million; the TTM value through Dec 2025 reached -$368.0 million, changed N/A, while the annual FY2025 figure was -$353.0 million, 25.18% down from the prior year.
  • EBT reached -$164.0 million in Q4 2025 per RCUS's latest filing, down from -$112.0 million in the prior quarter.
  • Across five years, EBT topped out at $281.5 million in Q4 2021 and bottomed at -$164.0 million in Q4 2025.
  • Average EBT over 5 years is -$57.5 million, with a median of -$74.0 million recorded in 2023.
  • The widest YoY moves for EBT: up 641.47% in 2021, down 4379.64% in 2021.
  • A 5-year view of EBT shows it stood at $281.5 million in 2021, then tumbled by 123.8% to -$67.0 million in 2022, then fell by 19.4% to -$80.0 million in 2023, then dropped by 15.0% to -$92.0 million in 2024, then crashed by 78.26% to -$164.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$164.0 million in Q4 2025, -$112.0 million in Q1 2025, and -$92.0 million in Q3 2024.